花旗:中国制药及生物科技ESMO数据再获验证 医药首选石药集团(01093.HK)及恒瑞医药(01276.HK)

智通财经
Nov 03
【花旗:中国制药及生物科技ESMO数据再获验证 医药首选石药集团(01093.HK)及恒瑞医药(01276.HK)】智通财经APP获悉,花旗发布研报称,ESMO 2026标志着中国制药及生物科技又迈出重要一步,中国原研资产于多项全球关键研究交出具说服力数据,并展现强劲的中国至全球一致性、高关注度临床结果,以及超越既有靶点的创新;这有助降低行业风险,提升对全球监管路径、海外商业化及跨境合作可持续性的信心,并可能支持具备差异化、具国际竞争力管线的公司结构性重估。医药板块首选石药集团(01093.HK)及恒瑞医药(01276.HK),生物制药板块首选信达生物(01801.HK)及科伦博泰生物(06990.HK),亦看好和黄医药(00013.HK)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10